Daunorubicin Hydrochloride - Uses, Dosage, Side Effects, Interaction

Daunorubicin is an anthracycline antibiotic that has antineoplastic activity and is used in the therapy of acute leukemia and AIDS-related Kaposi sarcoma. Daunorubicin is associated with a low rate of transient serum enzyme and bilirubin elevations during therapy but has not been implicated in cases of clinically apparent acute liver injury with jaundice.

Daunorubicin is an anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin. Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.

Daunorubicin is a natural product found in Actinomadura roseola. It has a role as an antineoplastic agent and a bacterial metabolite. It is an anthracycline, a member of tetracenequinones, a member of p-quinones, and an aminoglycoside antibiotic. It is a conjugate base of daunorubicin(1+). It derives from a hydride of tetracene.

Daunorubicin Hydrochloride is the hydrochloride salt of an anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin. Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.

Mechanism of Action

Daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Daunorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.

Daunorubicin is an antineoplastic antibiotic. Daunorubicin has antimitotic and cytotoxic activity. Daunorubicin forms a complex with DNA by intercalation between base pairs. By stabilizing the complex between DNA and topoisomerase II, daunorubicin inhibits the activity of this enzyme, resulting in single-strand and double-strand breaks in DNA. Daunorubicin also may inhibit polymerase activity, affect regulation of gene expression, and be involved in free radical damage to DNA. Although daunorubicin is maximally cytotoxic in the S phase, the drug is not cycle-phase specific. Daunorubicin also has antibacterial and immunosuppressive properties.

Anthracyclines are an important reagent in many chemotherapy regimes for treating a wide range of tumors. One of the primary mechanisms of anthracycline action involves DNA damage caused by inhibition of topoisomerase II. Enzymatic detoxification of anthracycline is a major critical factor that determines anthracycline resistance. Natural product, daunorubicin a toxic analogue of anthracycline is reduced to less toxic daunorubicinol by the AKR1B10, enzyme, which is overexpressed in most cases of smoking associate squamous cell carcinoma (SCC) and adenocarcinoma. In addition, AKR1B10 was discovered as an enzyme overexpressed in human liver, cervical and endometrial cancer cases in samples from uterine cancer patients. Also, the expression of AKR1B10 was associated with tumor recurrence after surgery and keratinization of squamous cell carcinoma in cervical cancer and estimated to have the potential as a tumor intervention target colorectal cancer cells (HCT-8) and diagnostic marker for non-small-cell lung cancer. This article presents the mechanism of daunorubicin action and a method to improve the effectiveness of daunorubicin by modulating the activity of AKR1B10.

Daunorubicin is an anthracycline antibiotic and antineoplastic agent. It acts by inhibiting cellular reproduction through interference with DNA replication although it may contribute to the induction of cell death by increasing oxidative stress through the generation of reactive oxygen species and free radicals. As an antineoplastic agent, daunorubicin carries significant toxicities including cytopenias, hepatotoxicity, and extravasation reactions. Like other anthracyclines, daunorubicin also exhibits cardiotoxicity in proportion with the cumulative dose received over time.

Indications

For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. Daunorubicin is indicated in combination with [cytarabine] for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
Daunorubicin is an anthracycline antibiotic that has antineoplastic activity and is used in the therapy of acute leukemia and AIDS-related Kaposi sarcoma.
Cerubidine in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
In addition to its major use in treating AML, daunorubicin is also used to treat neuroblastoma. Daunorubicin has been used with other chemotherapy agents to treat the blastic phase of chronic myelogenous leukemia.
DaunoXome is indicated as a first line cytotoxic therapy for advanced HIV-associated Kaposi’s sarcoma. DaunoXome is not recommended in patients with less than advanced HIV-related Kaposi’s sarcoma.
Daunorubicin is indicated in combination with cytarabine for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
Acute Lymphoblastic Leukemia (ALL)
Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Ewing’s Sarcoma
Lymphoma, Diffuse
Myeloblastic Leukemia
Myeloid Leukemia, Chronic, Chronic Phase
Non-Hodgkin’s Lymphoma (NHL)
Therapy-Related Acute Myeloid Leukemia
Wilms’ tumor

Use in Cancer

Daunorubicin hydrochloride is approved to be used with other drugs as remission induction therapy to treat:

Acute lymphoblastic leukemia in adults and children.
Acute myeloid leukemia in adults.

It is also being studied in the treatment of other types of cancer.

Contraindications

are allergic to daunorubicin or any ingredients of this medication
are breast-feeding
have already been treated with the maximum allowable lifetime dose of any anthracycline drug (daunorubicin, doxorubicin, epirubicin, idarubicin) or mitoxantrone
have heart failure
have low blood cell counts caused by previous cancer drug treatment or radiation therapy
are over the age of 75
a bacterial infection
opportunistic fungal infection
an infection due to a protozoa organism
decreased function of bone marrow
low levels of granulocytes, a type of white blood cell
low levels of a type of white blood cell called neutrophils
inflammation of the covering of the heart or pericardium
cardiomyopathy, a disease of the heart muscle
rapid ventricular heartbeat
abnormal heart rhythm
chronic heart failure
inflammation of the middle tissue heart muscle
liver problems
seizures
high amount of uric acid in the blood
pregnancy
a patient who is producing milk and breastfeeding
kidney disease with likely reduction in kidney function
an increased risk of developing an uncommon viral infection called an opportunistic infection

Dosage

Strengths: 20 mg; 5 mg/mL; 50 mg

Acute Nonlymphocytic Leukemia

Remission Induction in Combination:
Under 60 years:

45 mg/m2 IV once daily on days 1, 2, and 3 of the first course and on days 1 and 2 of subsequent courses AND cytosine arabinoside (ara-C) 100 mg/m2 IV once daily for 7 days for the first course and 5 days for subsequent courses
The attainment of a normal-appearing bone marrow may require up to 3 courses of induction.
The doses presented here are manufacturer suggested; consult local and institutional protocol for further guidance.
For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) in adults

Acute Lymphocytic Leukemia

Remission Induction in Combination:

45 mg/m2/day IV on days 1, 2, and 3 AND vincristine 2 mg IV on days 1, 8, and 15; prednisone 40 mg/m2/day orally on days 1 through 22, then tapered between days 22 to 29; L-asparaginase 500 IU/kg/day IV on days 22 through 32
The doses presented here are manufacturer suggested; consult local and institutional protocol for further guidance.

Acute Nonlymphocytic Leukemia

Remission Induction in Combination:
60 years and older:

30 mg/m2 IV once daily on days 1, 2, and 3 of the first course and on days 1 and 2 of subsequent courses AND cytosine arabinoside (ara-C) 100 mg/m2 IV once daily for 7 days for the first course and 5 days for subsequent courses
Duration of therapy: The attainment of a normal-appearing bone marrow may require up to 3 courses of induction.
The doses presented here are manufacturer suggested; consult local and institutional protocol for further guidance.
This daunorubicin dose-reduction is based on a single study and may not be appropriate if optimal supportive care is availabl
For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) in adults

Pediatric Dose

Acute Lymphocytic Leukemia

Remission Induction in Pediatric Acute Lymphocytic Leukemia:
In Combination:
LESS THAN 2 YEARS OR LESS THAN 0.5 M2:

1 mg/kg IV on day 1 every week, vincristine 1.5 mg/m2 IV on day 1 every week, prednisone 40 mg/m2 orally daily; complete remission will usually be obtained within 4 courses of therapy; however, if after 4 courses the patient is in partial remission, an additional 1 or 2 courses may be given to obtain complete remission

GREATER THAN 2 YEARS OR GREATER THAN 0.5 M2:

25 mg/m2 IV on day 1 every week, vincristine 1.5 mg/m2 IV on day 1 every week, prednisone 40 mg/m2 orally daily; complete remission will usually be obtained within 4 courses of therapy; however, if after 4 courses the patient is in partial remission, an additional 1 or 2 courses may be given to obtain complete remission
The doses presented here are manufacturer suggested; consult local and institutional protocol for further guidance.

Administration advice:

This drug is for IV use only and should not be administered by intramuscular or subcutaneous routes, as severe tissue necrosis will result.
This drug should be given into a rapidly flowing IV infusion of 0.9% sodium chloride or 5% dextrose injection.
The tubing should be connected to a butterfly needle, inserted preferably into a large vein. The dose and the size of the vein will determine the rate of administration, which should not be less than 3 to 5 minutes. Erythematous streaking and facial flushing are indications of too rapid administration.
A direct push injection is not recommended due to the risk of extravasation, which may occur even in the presence of adequate blood return upon needle aspiration.

Side Effects

The Most Common

abdominal pain
constipation
darkening of soles, palms, or nails
nausea
vomiting
sores in the mouth and throat
diarrhea
stomach pain
hair loss
red urine
redness, pain, swelling, or burning at the site where the injection was given
rash
hives
itching
difficulty breathing or swallowing

More Common

diarrhea
hot flashes
nausea and vomiting
reddish-coloured urine (not blood) – this is normal, and lasts 1 to 2 days after each dose
difficulty breathing,
swelling of your face, lips, tongue, or throat,
chest pain,
shortness of breath,
sores in your mouth and throat,
easy bruising,
unusual bleeding (nose, mouth, vagina, or rectum),
nausea,
upper stomach pain,
itching,
loss of appetite,
dark urine,
clay-colored stools,
yellowing of the skin or eyes (jaundice), and
pain, burning, irritation, or skin changes where the injection was given

Rare

reduction in number of menstrual periods
temporary total loss of hair (returns after treatments end)
skin rash or itching
sores in mouth and on lips
black, tarry stools
blood in urine
cough or hoarseness with fever or chills
fever or chills
irregular heartbeat or palpitations in the chest
lower back or side pain with fever or chills
pain at injection site
painful or difficult urination with fever or chills
pinpoint red spots on skin
shortness of breath or swelling of the lips, tongue, or face
swelling of feet and lower legs
unusual bleeding or bruising

Interaction

DRUG	INTERACTION
Abatacept	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Abatacept.
Abciximab	The risk or severity of bleeding can be increased when Abciximab is combined with Daunorubicin.
Abemaciclib	The metabolism of Abemaciclib can be decreased when combined with Daunorubicin.
Acalabrutinib	The metabolism of Acalabrutinib can be decreased when combined with Daunorubicin.
Acenocoumarol	The serum concentration of Acenocoumarol can be increased when it is combined with Daunorubicin.
Acetyldigitoxin	Acetyldigitoxin may decrease the cardiotoxic activities of Daunorubicin.
Acetylsalicylic acid	The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Daunorubicin.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Daunorubicin.
Adenovirus	The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Daunorubicin.
Afatinib	Afatinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Albendazole	The metabolism of Albendazole can be decreased when combined with Daunorubicin.
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Daunorubicin.
Alectinib	The metabolism of Alectinib can be decreased when combined with Daunorubicin.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Daunorubicin.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Daunorubicin.
Alfentanil	The metabolism of Alfentanil can be increased when combined with Daunorubicin.
Alfuzosin	The metabolism of Alfuzosin can be decreased when combined with Daunorubicin.
Allogeneic	The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Daunorubicin.
Allopurinol	The risk or severity of adverse effects can be increased when Allopurinol is combined with Daunorubicin.
Alpelisib	The metabolism of Alpelisib can be decreased when combined with Daunorubicin.
Alprazolam	The metabolism of Alprazolam can be decreased when combined with Daunorubicin.
Alteplase	The risk or severity of bleeding can be increased when Alteplase is combined with Daunorubicin.
Altretamine	The risk or severity of adverse effects can be increased when Altretamine is combined with Daunorubicin.
Ambrisentan	The metabolism of Ambrisentan can be increased when combined with Daunorubicin.
Aminophylline	The metabolism of Aminophylline can be decreased when combined with Daunorubicin.
Amiodarone	The metabolism of Amiodarone can be decreased when combined with Daunorubicin.
Amitriptyline	The metabolism of Amitriptyline can be increased when combined with Daunorubicin.
Amprenavir	The metabolism of Amprenavir can be increased when combined with Daunorubicin.
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Daunorubicin.
Anagrelide	The risk or severity of bleeding can be increased when Anagrelide is combined with Daunorubicin.
Anakinra	The risk or severity of adverse effects can be increased when Anakinra is combined with Daunorubicin.
Anastrozole	The risk or severity of cardiotoxicity can be increased when Daunorubicin is combined with Anastrozole.
Ancrod	The risk or severity of bleeding can be increased when Ancrod is combined with Daunorubicin.
Anifrolumab	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Anifrolumab.
Anistreplase	The risk or severity of bleeding can be increased when Anistreplase is combined with Daunorubicin.
immune globulin	The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Daunorubicin.
Anthrax vaccine	The risk or severity of infection can be increased when Anthrax vaccine is combined with Daunorubicin.
Antilymphocyte	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Antilymphocyte immunoglobulin (horse).
Antithrombin Alfa	The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Daunorubicin.
Antithrombin III human	The risk or severity of bleeding can be increased when Antithrombin III human is combined with Daunorubicin.
Antithymocyte	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Daunorubicin.
Apalutamide	Apalutamide may increase the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
Apixaban	The metabolism of Apixaban can be increased when combined with Daunorubicin.
Apomorphine	The metabolism of Apomorphine can be increased when combined with Daunorubicin.
Apremilast	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Apremilast.
Aprepitant	The metabolism of Aprepitant can be increased when combined with Daunorubicin.
Ardeparin	The risk or severity of bleeding can be increased when Ardeparin is combined with Daunorubicin.
Argatroban	The risk or severity of bleeding can be increased when Argatroban is combined with Daunorubicin.
Aripiprazole	The metabolism of Aripiprazole can be decreased when combined with Daunorubicin.
Aripiprazole lauroxil	The metabolism of Aripiprazole lauroxil can be decreased when combined with Daunorubicin.
Arsenic trioxide	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Arsenic trioxide.
Artemether	The metabolism of Artemether can be increased when combined with Daunorubicin.
Articaine	The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Articaine.
Astemizole	The metabolism of Astemizole can be decreased when combined with Daunorubicin.
COVID-19 Vaccine	The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Daunorubicin.
Asunaprevir	The metabolism of Asunaprevir can be increased when combined with Daunorubicin.
Atazanavir	Daunorubicin may decrease the excretion rate of Atazanavir which could result in a higher serum level.
Atenolol	Atenolol may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Atorvastatin	The metabolism of Atorvastatin can be decreased when combined with Daunorubicin.
Atropine	Atropine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Avanafil	Avanafil may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Avatrombopag	Avatrombopag may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Axitinib	The metabolism of Axitinib can be decreased when combined with Daunorubicin.
Azacitidine	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Azacitidine.
Azathioprine	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Azathioprine.
Azelastine	The metabolism of Azelastine can be increased when combined with Daunorubicin.
Azithromycin	The metabolism of Azithromycin can be decreased when combined with Daunorubicin.
Bacillus calmette	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Daunorubicin.
B live antigen	The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Daunorubicin.
Bacillus	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Daunorubicin.
Baricitinib	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Baricitinib.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Daunorubicin.
BCG vaccine	The risk or severity of infection can be increased when BCG vaccine is combined with Daunorubicin.
Beclomethasone	The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Daunorubicin.
Belantamab	Daunorubicin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Belatacept	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Belatacept.
Belimumab	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Belimumab.
Belinostat	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Belinostat.
Belumosudil	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Belumosudil.
Bemiparin	The risk or severity of bleeding can be increased when Bemiparin is combined with Daunorubicin.
Bendamustine	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Bendamustine.
Bendroflumethiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Daunorubicin.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Benzocaine.
Benzthiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Daunorubicin.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Benzyl alcohol.
Betamethasone	The risk or severity of adverse effects can be increased when Betamethasone is combined with Daunorubicin.
Betrixaban	The risk or severity of bleeding can be increased when Betrixaban is combined with Daunorubicin.
Bevacizumab	The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Daunorubicin.
Bexarotene	The risk or severity of adverse effects can be increased when Bexarotene is combined with Daunorubicin.
Bicalutamide	The metabolism of Bicalutamide can be decreased when combined with Daunorubicin.
Bimekizumab	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Bimekizumab.
Bivalirudin	The risk or severity of bleeding can be increased when Bivalirudin is combined with Daunorubicin.
Bleomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Daunorubicin.
Blinatumomab	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Blinatumomab.
Boceprevir	The metabolism of Boceprevir can be increased when combined with Daunorubicin.
Bordetella pertussis	The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Daunorubicin.
Bortezomib	The metabolism of Bortezomib can be decreased when combined with Daunorubicin.
Bosentan	Bosentan may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Bosutinib	The metabolism of Bosutinib can be decreased when combined with Daunorubicin.
Brentuximab vedotin	The metabolism of Brentuximab vedotin can be decreased when combined with Daunorubicin

You Might Also Read Abatacept; Uses, Dosage, Side Effects, Drug Interactions

Brigatinib	The metabolism of Brigatinib can be decreased when combined with Daunorubicin.
Brodalumab	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Brodalumab.
Budesonide	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Budesonide.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Bupivacaine.
Buprenorphine	Buprenorphine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Buspirone	The metabolism of Buspirone can be increased when combined with Daunorubicin.
Busulfan	The metabolism of Busulfan can be decreased when combined with Daunorubicin.
Butacaine	The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Butacaine.
Butamben	The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Butamben.
Cabazitaxel	The metabolism of Cabazitaxel can be decreased when combined with Daunorubicin.
Cabergoline	The metabolism of Cabergoline can be decreased when combined with Daunorubicin.
Caffeine	Caffeine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Canakinumab	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Canakinumab.
Cangrelor	The risk or severity of bleeding can be increased when Cangrelor is combined with Daunorubicin.
Cannabidiol	Cannabidiol may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Capecitabine	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Capecitabine.
Caplacizumab	The risk or severity of bleeding can be increased when Caplacizumab is combined with Daunorubicin.
Capmatinib	The serum concentration of Capmatinib can be decreased when it is combined with Daunorubicin.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Capsaicin.
Carbamazepine	The metabolism of Carbamazepine can be decreased when combined with Daunorubicin.
Carboplatin	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Carboplatin.
Carfilzomib	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Carfilzomib.
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Daunorubicin.
Cefaclor	Daunorubicin may decrease the excretion rate of Cefaclor which could result in a higher serum level.
Celecoxib	Celecoxib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Cenobamate	The metabolism of Cenobamate can be increased when combined with Daunorubicin.
Cephalexin	The metabolism of Cephalexin can be decreased when combined with Daunorubicin.
Ceritinib	The metabolism of Ceritinib can be decreased when combined with Daunorubicin.
Cerivastatin	Cerivastatin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Certolizumab pegol	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Certolizumab pegol.
Chlorambucil	The risk or severity of adverse effects can be increased when Chlorambucil is combined with Daunorubicin.
Chloramphenicol	The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Daunorubicin.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Chloroprocaine.
Chloroquine	The metabolism of Chloroquine can be increased when combined with Daunorubicin.
Chlorothiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Daunorubicin.
Chlorpheniramine	The metabolism of Chlorpheniramine can be increased when combined with Daunorubicin.
Chlorpromazine	Chlorpromazine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Cholesterol	Cholesterol may increase the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
Cholic Acid	Cholic Acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Ciclesonide	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ciclesonide.
Cilostazol	The metabolism of Cilostazol can be decreased when combined with Daunorubicin.
Cimetidine	Cimetidine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Cinchocaine.
Cisapride	The metabolism of Cisapride can be decreased when combined with Daunorubicin.
Cisplatin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Daunorubicin.
Cladribine	The risk or severity of adverse effects can be increased when Cladribine is combined with Daunorubicin.
Clarithromycin	Daunorubicin may decrease the excretion rate of Clarithromycin which could result in a higher serum level.
Clindamycin	The metabolism of Clindamycin can be increased when combined with Daunorubicin.
Clobetasol	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Clobetasol propionate.
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Daunorubicin.
Clofazimine	Clofazimine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Clomipramine	The metabolism of Clomipramine can be decreased when combined with Daunorubicin.
Clonidine	The metabolism of Clonidine can be decreased when combined with Daunorubicin.
Clopidogrel	The metabolism of Clopidogrel can be increased when combined with Daunorubicin.
Clostridium	The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Daunorubicin.
Clozapine	The risk or severity of neutropenia can be increased when Daunorubicin is combined with Clozapine.
Cobicistat	Cobicistat may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Cobimetinib	The metabolism of Cobimetinib can be decreased when combined with Daunorubicin.
Cocaine	The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Cocaine.
Colchicine	The metabolism of Colchicine can be decreased when combined with Daunorubicin.
Conivaptan	The metabolism of Conivaptan can be decreased when combined with Daunorubicin.
Copanlisib	The metabolism of Copanlisib can be decreased when combined with Daunorubicin.
Corticotropin	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Corticotropin.
Cortisone acetate	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Cortisone acetate.
Corynebacterium	The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Daunorubicin.
Crizotinib	The metabolism of Crizotinib can be decreased when combined with Daunorubicin.
Cyanocobalamin	The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Daunorubicin.
Cyclopenthiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Daunorubicin.
Cyclophosphamide	The metabolism of Cyclophosphamide can be decreased when combined with Daunorubicin.
Cyclosporine	Daunorubicin may increase the immunosuppressive activities of Cyclosporine.
Cyclothiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Daunorubicin.
Dabigatran	The risk or severity of bleeding can be increased when Dabigatran is combined with Daunorubicin.
Dabigatran etexilate	The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Daunorubicin.
Dabrafenib	The metabolism of Dabrafenib can be decreased when combined with Daunorubicin.
Dacarbazine	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dacarbazine.
Daclatasvir	Daclatasvir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Dacomitinib	The metabolism of Dacomitinib can be decreased when combined with Daunorubicin.
Dactinomycin	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dactinomycin.
Dalteparin	The risk or severity of bleeding can be increased when Dalteparin is combined with Daunorubicin.
Danaparoid	The risk or severity of bleeding can be increased when Danaparoid is combined with Daunorubicin.
Dapsone	The metabolism of Dapsone can be increased when combined with Daunorubicin.
Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Daunorubicin.
Darolutamide	Darolutamide may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Dasabuvir	Dasabuvir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Dasatinib	The metabolism of Dasatinib can be decreased when combined with Daunorubicin.
Decitabine	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Decitabine.
Defibrotide	The risk or severity of bleeding can be increased when Defibrotide is combined with Daunorubicin.
Deflazacort	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Deflazacort.
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Daunorubicin.
Deoxycholic acid	Deoxycholic acid may increase the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
Desirudin	The risk or severity of bleeding can be increased when Desirudin is combined with Daunorubicin.
Deslanoside	Deslanoside may decrease the cardiotoxic activities of Daunorubicin.
Desoximetasone	The risk or severity of adverse effects can be increased when Desoximetasone is combined with Daunorubicin.
Deucravacitinib	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Deucravacitinib.
Deutetrabenazine	The metabolism of Deutetrabenazine can be increased when combined with Daunorubicin.
Dexamethasone	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dexamethasone.
Dexamethasone acetate	Dexamethasone acetate may increase the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
Dexrazoxane	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Daunorubicin.
Dextran	The risk or severity of bleeding can be increased when Dextran is combined with Daunorubicin.
Dextromethorphan	The metabolism of Dextromethorphan can be increased when combined with Daunorubicin.

Diazepam	The metabolism of Diazepam can be increased when combined with Daunorubicin.
Diclofenac	Diclofenac may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Dicoumarol	The risk or severity of bleeding can be increased when Dicoumarol is combined with Daunorubicin.
Diethylstilbestrol	Diethylstilbestrol may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Difluocortolone	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Difluocortolone.
Digitoxin	The metabolism of Digitoxin can be decreased when combined with Daunorubicin.
Digoxin	Digoxin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Dihydroergocornine	The metabolism of Dihydroergocornine can be decreased when combined with Daunorubicin.
Dihydroergocristine	Daunorubicin may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.
Dihydroergotamine	The metabolism of Dihydroergotamine can be decreased when combined with Daunorubicin.
Diltiazem	The metabolism of Diltiazem can be increased when combined with Daunorubicin.
Dimethyl fumarate	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dimethyl fumarate.
Dinutuximab	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dinutuximab.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Diphenhydramine.
Dipyridamole	Daunorubicin may decrease the excretion rate of Dipyridamole which could result in a higher serum level.
Diroximel fumarate	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Diroximel fumarate.
Disulfiram	Daunorubicin may decrease the excretion rate of Disulfiram which could result in a higher serum level.
Docetaxel	The metabolism of Docetaxel can be decreased when combined with Daunorubicin.
Dofetilide	The metabolism of Dofetilide can be decreased when combined with Daunorubicin.
Domperidone	The metabolism of Domperidone can be increased when combined with Daunorubicin.
Doravirine	The metabolism of Doravirine can be increased when combined with Daunorubicin.
Doxazosin	The metabolism of Doxazosin can be decreased when combined with Daunorubicin.
Doxorubicin	The metabolism of Doxorubicin can be decreased when combined with Daunorubicin.
Dronabinol	The serum concentration of Dronabinol can be increased when it is combined with Daunorubicin.
Dronedarone	The metabolism of Dronedarone can be decreased when combined with Daunorubicin.
Drospirenone	The metabolism of Drospirenone can be decreased when combined with Daunorubicin.
Drotrecogin alfa	The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Daunorubicin.
Dutasteride	The metabolism of Dutasteride can be increased when combined with Daunorubicin.
Duvelisib	The metabolism of Duvelisib can be decreased when combined with Daunorubicin.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Dyclonine.
Ebastine	The metabolism of Ebastine can be decreased when combined with Daunorubicin.
Ebola Zaire	The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Daunorubicin.
Eculizumab	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Eculizumab.
Edetic acid	The risk or severity of bleeding can be increased when Edetic acid is combined with Daunorubicin.
Edoxaban	The risk or severity of bleeding can be increased when Edoxaban is combined with Daunorubicin.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Daunorubicin.
Efavirenz	Efavirenz may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Elbasvir	Elbasvir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Elexacaftor	The metabolism of Elexacaftor can be decreased when combined with Daunorubicin.
Eliglustat	The metabolism of Eliglustat can be decreased when combined with Daunorubicin.
Eltrombopag	Eltrombopag may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Emapalumab	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Emapalumab.
Enasidenib	The metabolism of Enasidenib can be decreased when combined with Daunorubicin.
Enoxaparin	The risk or severity of bleeding can be increased when Enoxaparin is combined with Daunorubicin.
Entrectinib	The metabolism of Entrectinib can be decreased when combined with Daunorubicin.
Enzalutamide	The serum concentration of Enzalutamide can be increased when it is combined with Daunorubicin.
Epirubicin	The risk or severity of adverse effects can be increased when Epirubicin is combined with Daunorubicin.
Eplerenone	The metabolism of Eplerenone can be increased when combined with Daunorubicin.
Epoprostenol	The risk or severity of bleeding can be increased when Epoprostenol is combined with Daunorubicin.
Eptifibatide	The risk or severity of bleeding can be increased when Eptifibatide is combined with Daunorubicin.
Erdafitinib	The metabolism of Erdafitinib can be decreased when combined with Daunorubicin.
Ergotamine	The metabolism of Ergotamine can be decreased when combined with Daunorubicin.
Eribulin	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Eribulin.
Erlotinib	The metabolism of Erlotinib can be decreased when combined with Daunorubicin.
Erythromycin	Erythromycin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Daunorubicin.
Estetrol	The metabolism of Estetrol can be decreased when combined with Daunorubicin.
Estradiol	Estradiol may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Estradiol acetate	Estradiol acetate may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Estradiol benzoate	Estradiol benzoate may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Estradiol cypionate	Estradiol cypionate may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Estradiol dienanthate	Estradiol dienanthate may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Estradiol valerate	Estradiol valerate may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Estramustine	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Estramustine.
Eszopiclone	The metabolism of Eszopiclone can be decreased when combined with Daunorubicin.
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Daunorubicin.
Ethinylestradiol	Ethinylestradiol may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Ethyl chloride.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Etidocaine.
Etoposide	The metabolism of Etoposide can be decreased when combined with Daunorubicin.
Everolimus	The metabolism of Everolimus can be decreased when combined with Daunorubicin.
Ezetimibe	Daunorubicin may decrease the excretion rate of Ezetimibe which could result in a higher serum level.
Famtozinameran	The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Daunorubicin.
Febuxostat	The excretion of Daunorubicin can be decreased when combined with Febuxostat.
Fedratinib	Fedratinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Felodipine	Daunorubicin may decrease the excretion rate of Felodipine which could result in a higher serum level.
Fenofibrate	Daunorubicin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Fentanyl	The metabolism of Fentanyl can be decreased when combined with Daunorubicin.
Fexinidazole	The metabolism of Fexinidazole can be increased when combined with Daunorubicin.
Filgotinib	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Filgotinib.
Finasteride	The metabolism of Finasteride can be increased when combined with Daunorubicin.
Finerenone	The serum concentration of Finerenone can be increased when it is combined with Daunorubicin.
Fingolimod	Daunorubicin may increase the immunosuppressive activities of Fingolimod.
Floxuridine	The risk or severity of adverse effects can be increased when Floxuridine is combined with Daunorubicin.
Flucloxacillin	Flucloxacillin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Flucytosine	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Flucytosine.
Fludarabine	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fludarabine.
Fludrocortisone	The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Daunorubicin.
Fluindione	The risk or severity of bleeding can be increased when Fluindione is combined with Daunorubicin.
Flunisolide	The risk or severity of adverse effects can be increased when Flunisolide is combined with Daunorubicin.
Fluocinolone acetonide	The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Daunorubicin.
Fluocinonide	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluocinonide.
Fluocortolone	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluocortolone.
Fluorescein	Fluorescein may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Fluorometholone	The risk or severity of adverse effects can be increased when Fluorometholone is combined with Daunorubicin.
Fluorouracil	The risk or severity of adverse effects can be increased when Fluorouracil is combined with Daunorubicin.
Flupentixol	The risk or severity of myelosuppression can be increased when Flupentixol is combined with Daunorubicin.
Fluprednisolone	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluprednisolone.
Flutamide	The metabolism of Flutamide can be increased when combined with Daunorubicin.
Fluticasone	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluticasone.

You Might Also Read Dapsone 5% Tropical Gel - Uses, Dosage, Side Effects

Fluvastatin	The metabolism of Fluvastatin can be increased when combined with Daunorubicin.
Fluvoxamine	Fluvoxamine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Fondaparinux	The risk or severity of bleeding can be increased when Fondaparinux is combined with Daunorubicin.
Fosaprepitant	The metabolism of Fosaprepitant can be decreased when combined with Daunorubicin.
Fosphenytoin	The metabolism of Fosphenytoin can be decreased when combined with Daunorubicin.
Fostamatinib	Fostamatinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Fostemsavir	Fostemsavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Fusidic acid	Fusidic acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Gallium nitrate	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Gallium nitrate.
Gefitinib	Gefitinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Gemcitabine	The risk or severity of adverse effects can be increased when Gemcitabine is combined with Daunorubicin.
Gemtuzumab ozogamicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daunorubicin.
Gilteritinib	Gilteritinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Glasdegib	Glasdegib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Glatiramer	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Glatiramer.
Glecaprevir	Glecaprevir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Glimepiride	Glimepiride may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Glipizide	Daunorubicin may decrease the excretion rate of Glipizide which could result in a higher serum level.
Glyburide	Glyburide may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Glycyrrhizic acid	Daunorubicin may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.
Golimumab	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Golimumab.
Grazoprevir	Grazoprevir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Guselkumab	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Guselkumab.
Haemophilus	The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Daunorubicin.
Halofantrine	The metabolism of Halofantrine can be increased when combined with Daunorubicin.
Haloperidol	The serum concentration of Haloperidol can be increased when it is combined with Daunorubicin.
Heparin	The risk or severity of bleeding can be increased when Heparin is combined with Daunorubicin.
Hepatitis A Vaccine	The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Daunorubicin.
Hepatitis B Vaccine	The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Daunorubicin.
Human adenovirus	The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Daunorubicin.
Hydrochlorothiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Daunorubicin.
Hydrocortisone	The metabolism of Hydrocortisone can be increased when combined with Daunorubicin.
Hydrocortisone	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Hydrocortisone acetate.
Hydrocortisone	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Hydrocortisone butyrate.
Hydrocortisone	The metabolism of Hydrocortisone cypionate can be increased when combined with Daunorubicin.
Hydrocortisone	The metabolism of Hydrocortisone phosphate can be increased when combined with Daunorubicin.
Hydrocortisone	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Hydrocortisone succinate.
Hydroflumethiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Daunorubicin.
Hydroxychloroquine	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Hydroxychloroquine.
Hydroxyprogesterone	The metabolism of Hydroxyprogesterone caproate can be increased when combined with Daunorubicin.
Hydroxyurea	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Hydroxyurea.
Hydroxyzine	The metabolism of Hydroxyzine can be increased when combined with Daunorubicin.
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daunorubicin.
Ibrutinib	The metabolism of Ibrutinib can be decreased when combined with Daunorubicin.
Icosapent ethyl	The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Daunorubicin.
Idarubicin	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Idarubicin.
Idelalisib	The metabolism of Idelalisib can be decreased when combined with Daunorubicin.
Ifosfamide	The metabolism of Ifosfamide can be decreased when combined with Daunorubicin.
Iloperidone	The metabolism of Iloperidone can be decreased when combined with Daunorubicin.
Iloprost	The risk or severity of bleeding can be increased when Iloprost is combined with Daunorubicin.
Imatinib	The risk or severity of adverse effects can be increased when Imatinib is combined with Daunorubicin.
Indinavir	Indinavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Indocyanine	Daunorubicin may decrease the excretion rate of Indocyanine green acid form which could result in a higher serum level.
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Daunorubicin.
Inebilizumab	The risk or severity of infection can be increased when Daunorubicin is combined with Inebilizumab.
Infigratinib	The metabolism of Infigratinib can be decreased when combined with Daunorubicin.
Infliximab	The risk or severity of adverse effects can be increased when Infliximab is combined with Daunorubicin.
Influenza	The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Daunorubicin.
Brisbane	The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Daunorubicin.
Influenza A virus	The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Daunorubicin.
Influenza A virus	The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Daunorubicin.
Influenza A virus	The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Daunorubicin.
Influenza A virus	The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Daunorubicin.
Influenza A virus	The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Daunorubicin.
Influenza A virus A	The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Daunorubicin.
Influenza A virus	The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Daunorubicin.
Influenza B virus	The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Daunorubicin.
Influenza B virus	The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Daunorubicin.
Influenza B virus	The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Daunorubicin.
Influenza B	The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Daunorubicin.
Interferon alfa-2a	The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Daunorubicin.
Interferon alfa-2b	The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Daunorubicin.
Interferon alfa-n1	The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Daunorubicin.
Interferon alfa-n3	The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Daunorubicin.
Interferon alfacon-1	The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Daunorubicin.
Interferon beta-1b	The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Daunorubicin.
Interferon gamma-1b	The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Daunorubicin.
Irinotecan	The metabolism of Irinotecan can be decreased when combined with Daunorubicin.
Isavuconazole	Isavuconazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Isradipine	Isradipine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Istradefylline	Istradefylline may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Itraconazole	Itraconazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Ivacaftor	The metabolism of Ivacaftor can be increased when combined with Daunorubicin.
Ivosidenib	The metabolism of Ivosidenib can be decreased when combined with Daunorubicin.
Ixabepilone	The metabolism of Ixabepilone can be decreased when combined with Daunorubicin.
Ixazomib	The metabolism of Ixazomib can be decreased when combined with Daunorubicin.
Ixekizumab	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ixekizumab.
COVID-19 Vaccine	The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Daunorubicin.
Japanese encephalitis	The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Daunorubicin.
Ketoconazole	Ketoconazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Lacosamide	The metabolism of Lacosamide can be decreased when combined with Daunorubicin.
Lansoprazole	Lansoprazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Lapatinib	The metabolism of Lapatinib can be increased when combined with Daunorubicin.
Lasmiditan	The serum concentration of Daunorubicin can be increased when it is combined with Lasmiditan.
Ledipasvir	Ledipasvir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Lefamulin	The metabolism of Lefamulin can be decreased when combined with Daunorubicin.
Leflunomide	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Leflunomide.
Lemborexant	The serum concentration of Lemborexant can be decreased when it is combined with Daunorubicin.

Pantoprazole	Pantoprazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Paritaprevir	Paritaprevir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Parnaparin	The risk or severity of bleeding can be increased when Parnaparin is combined with Daunorubicin.
Pazopanib	The metabolism of Pazopanib can be decreased when combined with Daunorubicin.
Pegaspargase	The risk or severity of adverse effects can be increased when Pegaspargase is combined with Daunorubicin.
Pegcetacoplan	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Pegcetacoplan.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Daunorubicin.
Peginterferon alfa-2a	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Daunorubicin.
Peginterferon alfa-2b	The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Daunorubicin.
Peginterferon beta-1a	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Peginterferon beta-1a.
Pemetrexed	The risk or severity of adverse effects can be increased when Pemetrexed is combined with Daunorubicin.
Penicillamine	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Penicillamine.
Pentamidine	The metabolism of Pentamidine can be increased when combined with Daunorubicin.
Pentosan polysulfate	The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Daunorubicin.
Pentostatin	The risk or severity of adverse effects can be increased when Pentostatin is combined with Daunorubicin.
Pentoxifylline	The risk or severity of bleeding can be increased when Pentoxifylline is combined with Daunorubicin.
Perampanel	The metabolism of Perampanel can be increased when combined with Daunorubicin.
Pertussis vaccine	The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Daunorubicin.
Pertuzumab	The risk or severity of cardiotoxicity can be increased when Daunorubicin is combined with Pertuzumab.
Pexidartinib	The metabolism of Pexidartinib can be decreased when combined with Daunorubicin.
Phenindione	The risk or severity of bleeding can be increased when Phenindione is combined with Daunorubicin.
Phenobarbital	Phenobarbital may increase the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
Phenol	The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Phenol.
Phenprocoumon	The metabolism of Phenprocoumon can be decreased when combined with Daunorubicin.
Phenylalanine	The risk or severity of adverse effects can be increased when Phenylalanine is combined with Daunorubicin.
Phenytoin	The metabolism of Phenytoin can be increased when combined with Daunorubicin.
Pibrentasvir	Pibrentasvir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Pimavanserin	The metabolism of Pimavanserin can be decreased when combined with Daunorubicin.
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Daunorubicin.
Pimozide	The metabolism of Pimozide can be decreased when combined with Daunorubicin.
Pirfenidone	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Pirfenidone.
Pitavastatin	Daunorubicin may decrease the excretion rate of Pitavastatin which could result in a higher serum level.
Polythiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Daunorubicin.
Pomalidomide	The metabolism of Pomalidomide can be decreased when combined with Daunorubicin.
Ponatinib	The metabolism of Ponatinib can be decreased when combined with Daunorubicin.
Ponesimod	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ponesimod.
Pralatrexate	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Pralatrexate.
Pralsetinib	Pralsetinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Pramocaine	The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Pramocaine.
Prasugrel	The risk or severity of bleeding can be increased when Prasugrel is combined with Daunorubicin.
Pravastatin	Pravastatin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Praziquantel	The metabolism of Praziquantel can be increased when combined with Daunorubicin.
Prednisolone	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Prednisolone.
Prednisone	The risk or severity of adverse effects can be increased when Prednisone is combined with Daunorubicin.
Pretomanid	The metabolism of Pretomanid can be decreased when combined with Daunorubicin.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Prilocaine.
Procaine	The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Procaine.
Procarbazine	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Procarbazine.
Progesterone	Progesterone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Proparacaine.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Propoxycaine.
Propranolol	The metabolism of Propranolol can be increased when combined with Daunorubicin.
Propylthiouracil	The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Daunorubicin.
Protein C	The risk or severity of bleeding can be increased when Protein C is combined with Daunorubicin.
Protein S human	The risk or severity of bleeding can be increased when Protein S human is combined with Daunorubicin.
Prucalopride	The metabolism of Prucalopride can be decreased when combined with Daunorubicin.
Quetiapine	The metabolism of Quetiapine can be increased when combined with Daunorubicin.
Quinidine	The metabolism of Quinidine can be decreased when combined with Daunorubicin.
Quinine	The metabolism of Quinine can be increased when combined with Daunorubicin.
Rabeprazole	Rabeprazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Rglobulin, human	The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Daunorubicin.
Rabies virus	The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Daunorubicin.
Rabies virus	The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Daunorubicin.
Raltitrexed	The risk or severity of adverse effects can be increased when Raltitrexed is combined with Daunorubicin.
Ranolazine	Ranolazine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Ravulizumab	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ravulizumab.
Regorafenib	The metabolism of Regorafenib can be decreased when combined with Daunorubicin.
Relugolix	The metabolism of Relugolix can be increased when combined with Daunorubicin.
Repaglinide	Daunorubicin may decrease the excretion rate of Repaglinide which could result in a higher serum level.
Reserpine	Reserpine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Retapamulin	The metabolism of Retapamulin can be decreased when combined with Daunorubicin.
Reteplase	The risk or severity of bleeding can be increased when Reteplase is combined with Daunorubicin.
Reviparin	The risk or severity of bleeding can be increased when Reviparin is combined with Daunorubicin.
Ribociclib	The metabolism of Ribociclib can be decreased when combined with Daunorubicin.
Rifampicin	Rifampicin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Rilonacept	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Rilonacept.
Rilpivirine	The serum concentration of Rilpivirine can be decreased when it is combined with Daunorubicin.
Rimegepant	The metabolism of Rimegepant can be increased when combined with Daunorubicin.
Ripretinib	Ripretinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Risankizumab	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Risankizumab.
Risperidone	The metabolism of Risperidone can be increased when combined with Daunorubicin.
Ritonavir	Ritonavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Daunorubicin.
Rivaroxaban	The metabolism of Rivaroxaban can be increased when combined with Daunorubicin.
Roflumilast	The serum concentration of Roflumilast can be increased when it is combined with Daunorubicin.
Rolapitant	Rolapitant may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Romidepsin	The metabolism of Romidepsin can be decreased when combined with Daunorubicin.
Ropeginterferon	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ropeginterferon alfa-2b.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Ropivacaine.
Rosiglitazone	Rosiglitazone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Rosuvastatin	Daunorubicin may decrease the excretion rate of Rosuvastatin which could result in a higher serum level.
Rotavirus vaccine	The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Daunorubicin.
Roxadustat	The serum concentration of Daunorubicin can be increased when it is combined with Roxadustat.
Rubella virus vaccine	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Daunorubicin.
Rucaparib	Rucaparib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Ruxolitinib	The metabolism of Ruxolitinib can be decreased when combined with Daunorubicin.
Safinamide	Safinamide may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Salmeterol	The metabolism of Salmeterol can be increased when combined with Daunorubicin.

You Might Also Read Is Naproxen Is Pregnancy Safe, Dosage, Warning

Saquinavir	Saquinavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Sarilumab	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Sarilumab.
Satralizumab	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Satralizumab.
Saxagliptin	The metabolism of Saxagliptin can be increased when combined with Daunorubicin.
Secukinumab	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Secukinumab.
Selpercatinib	The serum concentration of Selpercatinib can be decreased when it is combined with Daunorubicin.
Selumetinib	The metabolism of Selumetinib can be increased when combined with Daunorubicin.
Sildenafil	The metabolism of Sildenafil can be increased when combined with Daunorubicin.
Siltuximab	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Siltuximab.
Simeprevir	Simeprevir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Simvastatin	Simvastatin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Siponimod	The metabolism of Siponimod can be decreased when combined with Daunorubicin.
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Daunorubicin.
Sirolimus	The metabolism of Sirolimus can be decreased when combined with Daunorubicin.
Smallpox	The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Daunorubicin.
Sodium citrate	The risk or severity of bleeding can be increased when Sodium citrate is combined with Daunorubicin.
Sonidegib	The metabolism of Sonidegib can be decreased when combined with Daunorubicin.
Sorafenib	The metabolism of Sorafenib can be decreased when combined with Daunorubicin.
Sotagliflozin	Sotagliflozin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Spesolimab	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Spesolimab.
Spironolactone	Spironolactone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Stiripentol	The excretion of Daunorubicin can be decreased when combined with Stiripentol.
Streptokinase	The risk or severity of bleeding can be increased when Streptokinase is combined with Daunorubicin.
Streptozocin	The risk or severity of adverse effects can be increased when Streptozocin is combined with Daunorubicin.
Sulfamethoxazole	The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Daunorubicin.
Sulfasalazine	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Sulfasalazine.
Sulfinpyrazone	Daunorubicin may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.
Sulodexide	The risk or severity of bleeding can be increased when Sulodexide is combined with Daunorubicin.
Sunitinib	The metabolism of Sunitinib can be decreased when combined with Daunorubicin.
Suvorexant	The metabolism of Suvorexant can be decreased when combined with Daunorubicin.
Tacrolimus	The serum concentration of Tacrolimus can be increased when it is combined with Daunorubicin.
Tadalafil	The metabolism of Tadalafil can be increased when combined with Daunorubicin.
Tafamidis	The serum concentration of Daunorubicin can be increased when it is combined with Tafamidis.
Tamoxifen	The metabolism of Tamoxifen can be decreased when combined with Daunorubicin.
Tasimelteon	The metabolism of Tasimelteon can be decreased when combined with Daunorubicin.
Taurocholic acid	Taurocholic acid may increase the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
Tazemetostat	The metabolism of Tazemetostat can be decreased when combined with Daunorubicin.
Tedizolid phosphate	The risk or severity of myelosuppression can be increased when Daunorubicin is combined with Tedizolid phosphate.
Tegafur	The metabolism of Tegafur can be increased when combined with Daunorubicin.
Telaprevir	The metabolism of Telaprevir can be increased when combined with Daunorubicin.
Telithromycin	The metabolism of Telithromycin can be increased when combined with Daunorubicin.
Telmisartan	Telmisartan may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Temozolomide	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Temozolomide.
Temsirolimus	The metabolism of Temsirolimus can be decreased when combined with Daunorubicin.
Tenecteplase	The risk or severity of bleeding can be increased when Tenecteplase is combined with Daunorubicin.
Teniposide	The metabolism of Teniposide can be decreased when combined with Daunorubicin.
Tenofovir	The metabolism of Tenofovir alafenamide can be decreased when combined with Daunorubicin.
Tepotinib	Tepotinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Teprotumumab	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Teprotumumab.
Terfenadine	Terfenadine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Teriflunomide	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Teriflunomide.
Testosterone	The metabolism of Testosterone can be increased when combined with Daunorubicin.
Testosterone cypionate	The metabolism of Testosterone cypionate can be increased when combined with Daunorubicin.
Testosterone enanthate	The metabolism of Testosterone enanthate can be increased when combined with Daunorubicin.
Tetracaine	The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Tetracaine.
Tezacaftor	The metabolism of Tezacaftor can be increased when combined with Daunorubicin.
Thalidomide	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Thalidomide.
Theophylline	The metabolism of Theophylline can be decreased when combined with Daunorubicin.
Thiotepa	The metabolism of Thiotepa can be decreased when combined with Daunorubicin.
Ticagrelor	The metabolism of Ticagrelor can be increased when combined with Daunorubicin.
Tick-borne	The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Daunorubicin.
Ticlopidine	The risk or severity of bleeding can be increased when Ticlopidine is combined with Daunorubicin.
Tinidazole	Daunorubicin may decrease the excretion rate of Tinidazole which could result in a higher serum level.
Tinzaparin	The risk or severity of bleeding can be increased when Tinzaparin is combined with Daunorubicin.
Tioguanine	The risk or severity of adverse effects can be increased when Tioguanine is combined with Daunorubicin.
Tipranavir	Tipranavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Tirofiban	The risk or severity of bleeding can be increased when Tirofiban is combined with Daunorubicin.
Tivozanib	Tivozanib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Tixocortol	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Tixocortol.
Tocilizumab	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Tocilizumab.
Tofacitinib	The metabolism of Tofacitinib can be decreased when combined with Daunorubicin.
Tolvaptan	The metabolism of Tolvaptan can be decreased when combined with Daunorubicin.
Topotecan	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Topotecan.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Daunorubicin.
Trabectedin	The metabolism of Trabectedin can be decreased when combined with Daunorubicin.
Tramadol	The metabolism of Tramadol can be decreased when combined with Daunorubicin.
Trastuzumab	The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Daunorubicin.
Trastuzumab emtansine	The metabolism of Trastuzumab emtansine can be decreased when combined with Daunorubicin.
Trazodone	The metabolism of Trazodone can be increased when combined with Daunorubicin.
Tretinoin	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Tretinoin.
Triamcinolone	The risk or severity of adverse effects can be increased when Triamcinolone is combined with Daunorubicin.
Triazolam	The metabolism of Triazolam can be increased when combined with Daunorubicin.
Trichlormethiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Daunorubicin.
Trifluridine	The risk or severity of adverse effects can be increased when Trifluridine is combined with Daunorubicin.
Triflusal	The risk or severity of bleeding can be increased when Triflusal is combined with Daunorubicin.
Trilostane	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Trilostane.
Troglitazone	Troglitazone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Typhoid vaccine	The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Daunorubicin.
Typhoid Vaccine Live	The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Daunorubicin.
Typhoid Vi	The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Daunorubicin.
Udenafil	The metabolism of Udenafil can be increased when combined with Daunorubicin.
Upadacitinib	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Upadacitinib.
Urokinase	The risk or severity of bleeding can be increased when Urokinase is combined with Daunorubicin.
Ursodeoxycholic acid	Ursodeoxycholic acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Valbenazine	The metabolism of Valbenazine can be increased when combined with Daunorubicin.
Vandetanib	The metabolism of Vandetanib can be decreased when combined with Daunorubicin.
Vardenafil	The metabolism of Vardenafil can be decreased when combined with Daunorubicin.
Varicella zoster vaccine	The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Daunorubicin.
Varicella zoster	The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Daunorubicin.
Vedolizumab	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Vedolizumab.

Pregnancy and Lactation

Pregnancy Category D

Pregnancy

There is a possibility of birth defect if either the man or woman is using daunorubicin at the time of conception, or if it is taken during pregnancy. Effective birth control should be practiced while using this medication. This medication may harm the baby if used during pregnancy. Tell your doctor immediately if you become pregnant while using this medication.

Lactation

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Cerubidine (daunorubicin) , mothers should be advised to discontinue nursing during Cerubidine therapy.

How should this medicine be used?

Daunorubicin comes as a solution (liquid) or as a powder to be mixed with liquid to be injected intravenously (into a vein) by a doctor or nurse in a medical facility along with other chemotherapy medications. When daunorubicin is used to treat AML, it is usually injected once a day on certain days of your treatment period. When daunorubicin is used to treat ALL, it is usually injected once a week. The length of treatment depends on the types of drugs you are taking, how well your body responds to them, and the type of cancer you have. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

What special precautions should I follow?

Before receiving daunorubicin injection,

tell your doctor and pharmacist if you are allergic to daunorubicin, any other medications, or any of the ingredients in daunorubicin injection. Ask your pharmacist for a list of the ingredients.
tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention the medications listed in the IMPORTANT WARNING section and any of the following: azathioprine (Imuran), cyclosporine (Neoral, Sandimmune), methotrexate (Rheumatrex, Trexall), sirolimus (Rapamune), and tacrolimus (Prograf). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Other medications may also interact with daunorubicin, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
tell your doctor if you have or have ever had any medical condition.
tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. You should not become pregnant while you are receiving daunorubicin injection. If you become pregnant while receiving daunorubicin, call your doctor. Daunorubicin may harm the fetus.

References

https://www.cancer.gov/about-cancer/treatment/drugs/daunorubicinhydrochloride
https://pubchem.ncbi.nlm.nih.gov/compound/Daunorubicin
https://pubchem.ncbi.nlm.nih.gov/compound/Daunorubicin-hydrochloride
https://www.drugs.com/mtm/daunorubicin.html
https://www.ncbi.nlm.nih.gov/books/NBK559073/
https://www.webmd.com/drugs/2/drug-5021/daunorubicin-intravenous/details/list-contraindications
https://rxharun.com/daunorubicin-uses-dosage-side-effects-interactions/#gsc.tab=0
https://en.wikipedia.org/wiki/Daunorubicin
https://medlineplus.gov/druginfo/meds/a682289.html
https://go.drugbank.com/drugs/DB00694
ChEMBL
http://www.ebi.ac.uk/Information/termsofuse.html
https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL178/
ChEMBL Protein Target Tree
https://www.ebi.ac.uk/chembl/g/#browse/targets
Comparative Toxicogenomics Database (CTD)
http://ctdbase.org/about/legal.jsp
https://ctdbase.org/detail.go?type=chem&acc=D003630
Drug Gene Interaction database (DGIdb)
http://www.dgidb.org/downloads
https://www.dgidb.org/drugs/DAUNORUBICIN
DrugBank
https://www.drugbank.ca/legal/terms_of_use
Daunorubicin
https://www.drugbank.ca/drugs/DB00694
Therapeutic Target Database (TTD)
Daunorubicin
http://idrblab.net/ttd/data/drug/details/D01XWG
CAMEO Chemicals
https://cameochemicals.noaa.gov/help/reference/terms_and_conditions.htm?d_f=false
DAUNOMYCIN
https://cameochemicals.noaa.gov/chemical/16190
CAMEO Chemical Reactivity Classification
https://cameochemicals.noaa.gov/browse/react
CAS Common Chemistry
https://creativecommons.org/licenses/by-nc/4.0/
Daunorubicin
https://commonchemistry.cas.org/detail?cas_rn=20830-81-3
ChemIDplus
LICENSE
https://www.nlm.nih.gov/copyright.html
Daunorubicin [INN:BAN]
https://chem.nlm.nih.gov/chemidplus/sid/0020830813
ChemIDplus Chemical Information Classification
https://chem.nlm.nih.gov/chemidplus/
DTP/NCI
https://www.cancer.gov/policies/copyright-reuse
daunorubicin
https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=756717
EPA DSSTox
LICENSE
https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources
Daunorubicin
https://comptox.epa.gov/dashboard/DTXSID7022883
CompTox Chemicals Dashboard Chemical Lists
https://comptox.epa.gov/dashboard/chemical-lists/
European Chemicals Agency (ECHA)
https://echa.europa.eu/web/guest/legal-notice
Daunorubicin
https://echa.europa.eu/substance-information/-/substanceinfo/100.040.048
Daunorubicin
https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/94957
FDA Global Substance Registration System (GSRS)
https://www.fda.gov/about-fda/about-website/website-policies#linking
DAUNORUBICIN
https://gsrs.ncats.nih.gov/ginas/app/beta/substances/ZS7284E0ZP
Hazardous Substances Data Bank (HSDB)
DAUNORUBICIN
https://pubchem.ncbi.nlm.nih.gov/source/hsdb/5095
Human Metabolome Database (HMDB)
http://www.hmdb.ca/citing
Daunorubicin
http://www.hmdb.ca/metabolites/HMDB0014832
HMDB0014832_msms_2233133
https://hmdb.ca/metabolites/HMDB0014832#spectra
Haz-Map, Information on Hazardous Chemicals and Occupational Diseases
https://haz-map.com/About
Daunomycin
https://haz-map.com/Agents/2026
ChEBI
Daunorubicin
http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:41977
ChEBI Ontology
http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology
FDA Pharm Classes
https://www.fda.gov/about-fda/about-website/website-policies#linking
DAUNORUBICIN
https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm
FDA Pharmacological Classification
https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
LiverTox
LICENSE
https://www.nlm.nih.gov/copyright.html
Daunorubicin
https://www.ncbi.nlm.nih.gov/books/n/livertox/Daunorubicin/
LOTUS – the natural products occurrence database
https://lotus.nprod.net/
LOTUS Tree
https://lotus.naturalproducts.net/
NCI Thesaurus (NCIt)
https://www.cancer.gov/policies/copyright-reuse
https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C62091
NCI Thesaurus Tree
https://ncit.nci.nih.gov
CCSbase
https://ccsbase.net/
ClinicalTrials.gov
https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
https://clinicaltrials.gov/
DailyMed
LICENSE
https://www.nlm.nih.gov/copyright.html
CYTARABINE; DAUNORUBICIN
https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=CYTARABINE;+DAUNORUBICIN
DAUNORUBICIN
https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=DAUNORUBICIN
Drug Induced Liver Injury Rank (DILIrank) Dataset
https://www.fda.gov/about-fda/about-website/website-policies#linking
daunorubicin
https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset
Nature Chemical Biology
https://pubchem.ncbi.nlm.nih.gov/substance/866161
https://pubchem.ncbi.nlm.nih.gov/substance/24769892
https://pubchem.ncbi.nlm.nih.gov/substance/375991195
EU Clinical Trials Register
https://www.clinicaltrialsregister.eu/
FDA Orange Book
https://www.fda.gov/about-fda/about-website/website-policies#linking
Patent:7850990
https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
LIPID MAPS
Daunorubicin
https://lipidmaps.org/databases/lmsd/LMPK13050002
Lipid Classification
https://www.lipidmaps.org/
International Agency for Research on Cancer (IARC)
https://publications.iarc.fr/Terms-Of-Use
Daunomycin
https://monographs.iarc.who.int/list-of-classifications
IARC Classification
https://www.iarc.fr/
MassBank of North America (MoNA)
LICENSE
The content of the MoNA database is licensed under CC BY 4.0.
https://mona.fiehnlab.ucdavis.edu/documentation/license
DAUNORUBICIN
https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=compound.metaData%3Dq%3D%27name%3D%3D%22InChIKey%22%20and%20value%3D%3D%22STQGQHZAVUOBTE-VGBVRHCVSA-N%22%27
National Drug Code (NDC) Directory
https://www.fda.gov/about-fda/about-website/website-policies#linking
DAUNORUBICIN
https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
NCI Cancer Drugs
LICENSE
https://www.cancer.gov/policies/copyright-reuse
Cerubidine (Daunorubicin Hydrochloride)
https://www.cancer.gov/about-cancer/treatment/drugs/daunorubicinhydrochloride
NIPH Clinical Trials Search of Japan
https://rctportal.niph.go.jp/en/
NLM RxNorm Terminology
https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html
daunorubicin
https://rxnav.nlm.nih.gov/id/rxnorm/3109
NORMAN Suspect List Exchange
LICENSE
Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0
https://creativecommons.org/licenses/by/4.0/
NORMAN Suspect List Exchange Classification
https://www.norman-network.com/nds/SLE/
WHO Anatomical Therapeutic Chemical (ATC) Classification
https://www.whocc.no/copyright_disclaimer/
https://www.whocc.no/atc/
ATC Code
https://www.whocc.no/atc_ddd_index/
Protein Data Bank in Europe (PDBe)
http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/DM1
PubChem
https://pubchem.ncbi.nlm.nih.gov
RCSB Protein Data Bank (RCSB PDB)
https://www.rcsb.org/pages/policies
https://www.rcsb.org/
SpectraBase
DAUNOMYCIN
https://spectrabase.com/spectrum/3VW4DwufjFT
https://spectrabase.com/spectrum/KyvBXEaNjqC
Springer Nature
https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=38061049-802281767
Thieme Chemistry
https://creativecommons.org/licenses/by-nc-nd/4.0/
https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=38061049-802269208
WHO Model Lists of Essential Medicines
https://www.who.int/about/who-we-are/publishing-policies/copyright
Daunorubicin
https://list.essentialmeds.org/medicines/85
Wikidata
LICENSE
CCZero
https://creativecommons.org/publicdomain/zero/1.0/
Daunorubicin
https://www.wikidata.org/wiki/Q411659
Wiley
https://pubchem.ncbi.nlm.nih.gov/substance/?source=wiley&sourceid=125302
Medical Subject Headings (MeSH)
https://www.nlm.nih.gov/copyright.html
Daunorubicin
https://www.ncbi.nlm.nih.gov/mesh/68003630
MeSH Tree
http://www.nlm.nih.gov/mesh/meshhome.html
Antibiotics, Antineoplastic
https://www.ncbi.nlm.nih.gov/mesh/68000903
Topoisomerase II Inhibitors
https://www.ncbi.nlm.nih.gov/mesh/68059005
KEGG
https://www.kegg.jp/kegg/legal.html
Lipids
http://www.genome.jp/kegg-bin/get_htext?br08002.keg
Anatomical Therapeutic Chemical (ATC) classification
http://www.genome.jp/kegg-bin/get_htext?br08303.keg
Target-based classification of drugs
http://www.genome.jp/kegg-bin/get_htext?br08310.keg
Drug Groups
http://www.genome.jp/kegg-bin/get_htext?br08330.keg
UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)
GHS Classification Tree
http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
PATENTSCOPE (WIPO)
SID 390638707
https://pubchem.ncbi.nlm.nih.gov/substance/390638707
SID 403391290
https://pubchem.ncbi.nlm.nih.gov/substance/403391290
NCBI
https://www.ncbi.nlm.nih.gov/projects/linkout

Mechanism of Action

Indications

Use in Cancer

Contraindications

Dosage

Acute Nonlymphocytic Leukemia

Acute Lymphocytic Leukemia

Acute Nonlymphocytic Leukemia

Pediatric Dose

Acute Lymphocytic Leukemia

Side Effects

The Most Common

More Common

Rare

Interaction

Pregnancy and Lactation

Pregnancy

Lactation

How should this medicine be used?

What special precautions should I follow?

Before receiving daunorubicin injection,

Share this:

Related